Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
Marek
Kenneth
K
Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA. kmarek@indd.org
Jennings
Danna
D
Seibyl
John
J
D002986:Clinical Trials as Topic; D003342:Corpus Striatum / Q000098:blood supply* / Q000378:metabolism*; D018450:Disease Progression; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013378:Substantia Nigra / Q000098:blood supply* / Q000378:metabolism*; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D018491:Dopamine Agonists; D019275:Radiopharmaceuticals; D004298:Dopamine